Treace to Report Second Quarter 2022 Financial Results on August 9, 2022
PONTE VEDRA, Fla., July 22, 2022 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace”) (NasdaqGS: TMCI), a medical technology company...
Year: 2022
Mersana Therapeutics Chief People Officer Carla Poulson Named One of Savoy Magazine’s 2022 Most Influential Black Executives in Corporate America
Carla Poulson, Chief People Officer of Mersana Carla Poulson, Chief People Officer of Mersana, has been named as one of...
Alimera Announces Pricing and Reimbursement of Uveitis Indication Granted for ILUVIEN® in France
Partner Horus Pharma to launch ILUVIEN for non-infectious uveitis affecting the posterior segment indication later in Q3ATLANTA, July 22, 2022...
Fortress Biotech Appoints David Jin as Chief Financial Officer
MIAMI, July 22, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress” or the “Company”), an innovative biopharmaceutical company...
ORYZON Reports Results and Corporate Update for Half-Year Ending June 30, 2022
Oryzon invests $8.1 million in R&D in the first half 2022MADRID, Spain and BOSTON, July 22, 2022 (GLOBE NEWSWIRE) --...
XORTX Reports Annual & Special Meeting Results
CALGARY, Alberta, July 22, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX...
PepGen Appoints Caroline Godfrey, Ph.D. to the Company’s Scientific Advisory Board
BOSTON, July 22, 2022 (GLOBE NEWSWIRE) -- PepGen Inc. (“PepGen”), a Boston-based clinical-stage biotechnology company advancing the next generation of...
CloudMD Finalizes Review and Settlement of the VisionPros Acquisition
VANCOUVER, British Columbia, July 22, 2022 (GLOBE NEWSWIRE) -- CloudMD Software & Services Inc. (TSXV: DOC, OTCQX: DOCRF, Frankfurt: 6PH)...
VitalHub Corp. Announces Results of Annual General and Special Meeting of Shareholders
TORONTO, July 22, 2022 (GLOBE NEWSWIRE) -- VITALHUB CORP. (TSX: VHI) (the “Company” or “VitalHub”) today reported a summary of...
CHMP recommends EU approval of Roche’s Vabysmo, the first bispecific antibody for the eye, for two leading causes of vision loss
Vabysmo (faricimab) simultaneously targets and inhibits two disease pathways that drive neovascular or “wet” age-related macular degeneration (nAMD) and diabetic...
H-CYTE to Expect the Completed Acquisition of Jantibody Within 30 Days
Addition of Immunotherapeutic Agent Under Investigation for the Treatment of Ovarian Cancer to Asset PortfolioTAMPA, Fla., July 22, 2022 (GLOBE...
Institute of Biomedical Research Corp Announces Purchase of Biomedical and Nutraceutical Assets
SEATTLE, WA, July 22, 2022 (GLOBE NEWSWIRE) -- Institute of Biomedical Research Corp. (OTC Pink: MRES), a diversified biomedical company,...
ITM Appoints Dr. Sebastian Marx as Chief Business Officer and Member of Executive Board
CBO Sebastian Marx Image of ITM SE CBO Sebastian MarxGarching / Munich, July 22, 2022 – ITM Isotope Technologies Munich...
Bavarian Nordic Receives Positive CHMP Opinion on the Extension of Vaccine Label to Include Monkeypox
COPENHAGEN, Denmark, July 22, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Committee for Medicinal Products for...
Pixium Vision announces its financial results for H1 2022 and provides a business update
Pixium Vision announces its financial results for H1 2022 and provides a business update Cash position at 30 June 2022:...
Addex Raises $4.2 million in Equity Financing
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 22, 2022 – Addex Therapeutics Ltd (SIX: ADXN and...
Cancer Research UK and Sosei Heptares sign agreement to advance cancer immunotherapy candidate into clinical trials
HTL0039732 is a novel EP4 antagonist with potential to treat a wide range of cancers in combination with other immunotherapiesTOKYO,...
MediciNova Initiates Clinical Evaluation of a New Parenteral Formulation of MN-166 (ibudilast)
LA JOLLA, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market...
Simply Better Brands Corp. Announces a Non-Brokered Private Placement of up to $9.1 Million Secured Convertible Debentures and up to $3.25 Million Common Shares to Reduce Debt and Fuel Growth
VANCOUVER, British Columbia, July 21, 2022 (GLOBE NEWSWIRE) -- Simply Better Brands Corp. (the “Company” or “Simply Better Brands”) (TSX...
ClearPoint Neuro Congratulates Partner PTC Therapeutics on Being Granted Marketing Authorization by the European Commission for Upstaza™ – First Disease-Modifying Treatment for AADC Deficiency
First Gene Therapy Approved for Direct Infusion into the Brain will be Administered with ClearPoint’s SmartFlow® Neuro CannulaSOLANA BEACH, Calif.,...